Oxford BioMedica PLC (LSE:OXB) has reported a strong start to fiscal year 2025, with first-half revenues reaching £70-73 million. This represents a 38% to 44% increase compared to the same period in 2024. The company secured £149 million in new orders during H1 2025, more than doubling the previous year’s figures, and has reaffirmed its full-year revenue guidance of £160-170 million.
The company’s multi-vector, multi-site strategy is advancing well, supported by increased demand for its services and a robust order book that provides confidence in future growth. Oxford BioMedica is expanding its manufacturing and development capacity, particularly in late-stage lentiviral programs, and is enhancing its global operations to support clients across different geographies and development stages.
While the company’s strong corporate events and positive technical indicators underpin a favorable outlook, concerns remain regarding financial performance and valuation. Financial stability continues to be a key risk despite Oxford BioMedica’s strategic initiatives and market position.
More about Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience in viral vectors, the company collaborates with leading pharmaceutical and biotech firms to provide expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford BioMedica offers services spanning early-stage development through commercialization, supported by strong quality assurance and regulatory capabilities. The company is headquartered in Oxford, UK, with facilities in the UK, France, and the US.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply